These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 24026012

  • 1. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ.
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [Abstract] [Full Text] [Related]

  • 2. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ, Wang ZJ, De W, Zheng M, Xu WZ, Wu HF, Armstrong A, Zhu JG.
    Oncotarget; 2017 Jun 20; 8(25):41064-41077. PubMed ID: 28455956
    [Abstract] [Full Text] [Related]

  • 3. RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression.
    Huang S, Zhang J, Wu X, Liang B, Pang N, Yang L, Zhang Z.
    Life Sci; 2024 Aug 15; 351():122849. PubMed ID: 38897346
    [Abstract] [Full Text] [Related]

  • 4. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG.
    Nat Genet; 2012 Jul 01; 44(8):852-60. PubMed ID: 22751098
    [Abstract] [Full Text] [Related]

  • 5. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F, Li J, Jang C, Wang J, Xiong J.
    Int J Clin Exp Pathol; 2014 Jul 01; 7(10):6653-61. PubMed ID: 25400744
    [Abstract] [Full Text] [Related]

  • 6. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A, Brägelmann J, Billig H, Thewes B, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Brossart P, Kirfel J, Perner S.
    Int J Mol Sci; 2016 Dec 22; 18(1):. PubMed ID: 28025482
    [Abstract] [Full Text] [Related]

  • 7. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7.
    Kalinowski FC, Giles KM, Candy PA, Ali A, Ganda C, Epis MR, Webster RJ, Leedman PJ.
    PLoS One; 2012 Dec 22; 7(10):e47067. PubMed ID: 23115635
    [Abstract] [Full Text] [Related]

  • 8. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
    Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A.
    Cancer Biol Ther; 2010 Nov 15; 10(10):1009-18. PubMed ID: 20818175
    [Abstract] [Full Text] [Related]

  • 9. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, Gabra H, Thiery JP, Huang RY.
    Sci Signal; 2016 Oct 04; 9(448):ra97. PubMed ID: 27703030
    [Abstract] [Full Text] [Related]

  • 10. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
    Bansal N, Mishra PJ, Stein M, DiPaola RS, Bertino JR.
    Oncotarget; 2015 Jun 20; 6(17):15321-31. PubMed ID: 26036314
    [Abstract] [Full Text] [Related]

  • 11. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype.
    Ciardiello D, Blauensteiner B, Matrone N, Belli V, Mohr T, Vitiello PP, Martini G, Poliero L, Cardone C, Napolitano S, De Falco V, Giunta EF, Ciaramella V, Corte CD, Barra G, Selvaggi F, Franco R, Marino FZ, Cuomo A, Morgillo F, Troiani T, Sibilia M, Ciardiello F, Martinelli E.
    Med Oncol; 2021 Feb 11; 38(3):24. PubMed ID: 33570712
    [Abstract] [Full Text] [Related]

  • 12. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
    Wang Y, Xia H, Zhuang Z, Miao L, Chen X, Cai H.
    Cell Death Dis; 2014 May 15; 5(5):e1227. PubMed ID: 24832599
    [Abstract] [Full Text] [Related]

  • 13. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM, Rodriguez BL, Padhye A, Ochieng JK, Gibson L, Diao L, Fowlkes NW, Fradette JJ, Peng DH, Cardnell RJ, Kovacs JJ, Wang J, Byers LA, Gibbons DL.
    Cancer Res; 2021 Mar 01; 81(5):1398-1412. PubMed ID: 33402388
    [Abstract] [Full Text] [Related]

  • 14. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
    Woo SM, Min KJ, Seo SU, Kim S, Kubatka P, Park JW, Kwon TK.
    Int J Mol Sci; 2019 Jul 02; 20(13):. PubMed ID: 31269715
    [Abstract] [Full Text] [Related]

  • 15. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
    Scherschinski L, Prem M, Kremenetskaia I, Tinhofer I, Vajkoczy P, Karbe AG, Onken JS.
    Int J Mol Sci; 2022 Jan 17; 23(2):. PubMed ID: 35055167
    [Abstract] [Full Text] [Related]

  • 16. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.
    Clin Cancer Res; 2013 Jan 01; 19(1):279-90. PubMed ID: 23091115
    [Abstract] [Full Text] [Related]

  • 17. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
    Vouri M, An Q, Birt M, Pilkington GJ, Hafizi S.
    Oncotarget; 2015 Jun 30; 6(18):16183-97. PubMed ID: 25980499
    [Abstract] [Full Text] [Related]

  • 18. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
    Tsukita Y, Fujino N, Miyauchi E, Saito R, Fujishima F, Itakura K, Kyogoku Y, Okutomo K, Yamada M, Okazaki T, Sugiura H, Inoue A, Okada Y, Ichinose M.
    Mol Cancer; 2019 Feb 11; 18(1):24. PubMed ID: 30744655
    [Abstract] [Full Text] [Related]

  • 19. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y.
    Cancer Res; 2010 Feb 15; 70(4):1544-54. PubMed ID: 20145120
    [Abstract] [Full Text] [Related]

  • 20. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
    Iida M, McDaniel NK, Kostecki KL, Welke NB, Kranjac CA, Liu P, Longhurst C, Bruce JY, Hong S, Salgia R, Wheeler DL.
    BMC Cancer; 2022 Apr 23; 22(1):447. PubMed ID: 35461210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.